Press Release: Antitrust: Commission closes investigation into generic pharmaceutical companies in France

On 9 July 2014, the European Commission closed its antitrust investigation into generic pharmaceutical companies in France. The investigation focused on suspected coordination between generic pharmaceutical companies when negotiating an initial price with the French pricing authority before launching a new generic product.

European Union antitrust regulators fined French drugmaker Servier, Israel's Teva and four others a total of €428 million.

European Commission: RAPID: PR/14/799: Antitrust: Commission fines Servier and five generic companies for curbing entry of cheaper versions of cardiovascular medicine http://europa.eu/rapid/press-release_IP-14-799_en.pdf

EUObserver, 09.7.14: EU fines pharma-giants €427mn in ‘pay for delay’ case http://euobserver.com/news/124917

EurActiv, 09.07.14: EU fines pharma companies for drug-delay deals http://www.euractiv.com/sections/health-consumers/eu-fines-pharma-companies-drug-delay-deals-303383

Deutsche Welle, 09.07.14: EU fines Servier, generics firms for blocking cheap drugs http://dw.de/p/1CYuq

ESO: Background information: Antitrust: Commission sends Statement of Objections on perindopril to Servier and others http://www.europeansources.info/record/press-release-antitrust-commission-sends-statement-of-objections-on-perindopril-to-servier-and-others/

---